The BACH1 Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line, designed to disrupt the BACH1 gene and create a loss-of-function model for transcriptional regulation studies. This polyclonal pool, originating from a heterogeneous editing event, enables functional interrogation of BACH1 without clonal selection, preserving diverse genetic backgrounds to better represent population-level responses. The product serves as a critical tool for investigating oxidative stress response, cancer biology, and drug resistance mechanisms in a physiologically relevant pulmonary epithelial context.
The parental A-549 cell line is a widely used in vitro model of alveolar type II pulmonary epithelium, established from a human lung adenocarcinoma. These cells retain key characteristics of the distal lung epithelium, including surfactant production and metabolic activity, making them suitable for studying non-small cell lung cancer, chronic obstructive pulmonary disease, and solid tumor biology. A-549 cells exhibit robust growth and are amenable to genetic manipulation, providing an ideal host for examining gene function in oncogenesis and oxidative damage response.
BACH1 encodes a transcriptional repressor that operates as a critical node in the KEAP1-NRF2 antioxidant response pathway, directly binding to antioxidant response elements (AREs) in the promoters of target genes such as HMOX1 and NQO1 to suppress their expression under homeostatic conditions. BACH1 activity is regulated by heme binding, which induces its nuclear export and degradation, and by reactive oxygen species (ROS) that modulate its interaction with small MAF proteins (MAFK, MAFG) and the NuRD corepressor complex. Downstream of MAPK/ERK signaling, BACH1 also influences the expression of metastasis-related genes including CXCR4, MMP1, and MMP9, linking oxidative stress responses to cell migration and invasion. BACH1 knockout in A-549 cells disrupts this repression, leading to constitutive activation of ARE-dependent transcription and profound shifts in cellular redox balance.
In the A-549 lung adenocarcinoma model, BACH1 knockout rewires the transcriptional network, derepressing HMOX1 and NQO1 to enhance the antioxidant capacity and potentially alter sensitivity to chemotherapeutics like cisplatin. Loss of BACH1 function also impacts cell cycle progression and diminishes the invasive potential through reduced MMP expression, while simultaneously activating NRF2-mediated survival programs. These changes make the knockout model particularly valuable for dissecting the interplay between oncogenic signaling??via MAPK and Wnt/??-catenin pathways??and oxidative stress adaptation in lung cancer progression and metastasis.
Research applications for this polyclonal knockout population span multiple domains, including mechanistic studies of ARE-dependent gene regulation using chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR), gene expression analysis by RNA-seq and RT-qPCR for targets such as HMOX1 and NQO1, and protein-level confirmation via western blotting and immunofluorescence. The model is well-suited for functional assays measuring reactive oxygen species levels by flow cytometry, migration and invasion potential in Boyden chamber setups, and drug sensitivity profiling under oxidative stress inducers or standard chemotherapeutic agents. These uses facilitate the development of antioxidant therapeutic strategies and investigation of resistance mechanisms in lung adenocarcinoma. For further details and custom inquiries, please contact Ascent Research.
